Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open-label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in high-risk, triple-positive patients with antiphospholipid syndrome.

Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure

Prisco, Domenico;Barcellona, Doris;
2021-01-01

Abstract

Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open-label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in high-risk, triple-positive patients with antiphospholipid syndrome.
File in questo prodotto:
File Dimensione Formato  
2020 JTH (1).pdf

Solo gestori archivio

Tipologia: versione post-print
Dimensione 5.92 MB
Formato Adobe PDF
5.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/302343
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 32
social impact